Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Yixie Granules is an investigational oral formulation developed by Beijing Humanwell Junwei Pharmaceutical Technology Development, a subsidiary of Humanwell Healthcare. It is being developed for the treatment of hyperuricemia in the non-acute phase of gout and the Traditional Chinese Medicine (TCM) syndrome of stasis of dampness and turbidness. The drug is classified as a Chemical Category 1 innovative drug in China, suggesting it is a modernized or purified formulation derived from traditional components, specifically the rhizome of *Dioscorea* species (known as Yixie in TCM). It aims to lower serum uric acid levels by promoting the excretion of metabolic waste products, addressing the underlying dampness and turbidity associated with gouty conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Yixie Granules.